Vincent Cariati, MD
Internal Medicine · Phoenix, AZNPI 1558459776
Payments from drug & device makers
Across 264 payments — averaging $20.07 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$606
- CSL Behring$572
- Sanofi$540
- Regeneron Healthcare Solutions, Inc.$427
- Takeda Pharmaceuticals U.S.A., Inc.$404
- Pfizer$370
- plus $2K from 33 others
What the payments were for
- Consulting fees$341%
- Food & beverage$5,26599%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 19 | $606 |
| CSL Behring | 22 | $572 |
| Sanofi | 20 | $540 |
| Regeneron Healthcare Solutions, Inc. | 23 | $427 |
| Takeda Pharmaceuticals U.S.A., Inc. | 51 | $404 |
| Pfizer | 17 | $370 |
| Grifols USA, LLC | 13 | $303 |
| Novo Nordisk | 10 | $164 |
| Johnson & Johnson | 9 | $162 |
| GSK | 8 | $142 |
| Baxter Healthcare | 7 | $126 |
| Boston Scientific | 1 | $121 |
| Lilly USA, LLC | 7 | $117 |
| Blueprint Medicines Corporation | 4 | $115 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 6 | $104 |
| Biocryst US Sales Co., LLC | 5 | $102 |
| Genentech USA, Inc. | 3 | $90 |
| ARS Pharmaceuticals Operations, Inc. | 4 | $87 |
| Novartis | 3 | $76 |
| Amgen | 3 | $67 |
| LEO Pharma Inc. | 2 | $58 |
| Kaleo, Inc. | 2 | $54 |
| Pharming Healthcare, Inc. | 2 | $48 |
| AbbVie | 3 | $48 |
| Optinose US, Inc. | 2 | $44 |
| Mylan Specialty L.p. | 2 | $42 |
| E.r. Squibb & Sons, L.L.C. | 2 | $38 |
| ADMA Biomanufacturing LLC | 2 | $34 |
| Exact Sciences | 1 | $33 |
| Electromed, Inc. | 2 | $32 |
| Biohaven Pharmaceutical Holding Company Ltd. | 1 | $27 |
| Nevro Corp. | 1 | $21 |
| Astellas Pharma US Inc | 1 | $20 |
| Philips North America LLC | 1 | $19 |
| Phadia US Inc. | 1 | $18 |
| Eisai Inc. | 1 | $18 |
| Kedrion Biopharma, Inc. | 1 | $17 |
| Amneal Pharmaceuticals LLC | 1 | $15 |
| Vistapharm, Inc. | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- AIRSUPRA$125
- BREZTRI$125
- WATCHMAN Access System$121
- DUPIXENT$113
How this compares
$5,299 in reported general payments places this provider in the 90th percentile of 2,212 internal medicine providers in Arizona.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| FarxigaDapagliflozin Propanediol | 60 | $69,731 |
| MounjaroTirzepatide | 50 | $66,791 |
| EliquisApixaban | 48 | $47,560 |
| OzempicSemaglutide | 22 | $38,023 |
| TrulicityDulaglutide | 12 | $21,271 |
| XareltoRivaroxaban | 18 | $16,850 |
| Repatha SureclickEvolocumab | 13 | $11,744 |
| Oxycodone Hcl | 162 | $3,868 |
| Gabapentin | 128 | $2,652 |
| Levothyroxine Sodium | 249 | $2,218 |
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 88 | $2,069 |
| Celecoxib | 65 | $2,055 |
| Pregabalin | 30 | $1,913 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 15 | $1,868 |
| Atorvastatin Calcium | 247 | $1,583 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCMounjaro, Trulicity | $117 | $88,06262 claims |
| AstraZenecaFarxiga | $606 | $69,73160 claims |
| PfizerEliquis, Paxlovid | $370 | $48,92759 claims |
| Novo NordiskOzempic | $164 | $38,02322 claims |
| Johnson & JohnsonXarelto | $162 | $16,85018 claims |
| Amneal Pharmaceuticals LLCLevothyroxine Sodium | $15 | $2,218249 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 2,212 internal medicine providers in Arizona.
Other internal medicine in Phoenix
- Louise TaberPhoenix$8.5M
- Ernie RifferPhoenix$3M
- Frank LovecchioPhoenix$945K
- Allison PerrinPhoenix$861K
- Nasser HajaigPhoenix$687K
- Richard TayrienPhoenix$299K
- Sanjay ShahPhoenix$288K
- Kelly KrohnPhoenix$262K
- Paul WaxPhoenix$243K
- Paul StanderPhoenix$222K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.